Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,734 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Matrix metalloproteinase 12 promotes tumor propagation in the lung.
Ella E, Harel Y, Abraham M, Wald H, Benny O, Karsch-Bluman A, Vincent D, Laurent D, Amir G, Izhar U, Shapira OM, Yoon D, Lee HS, Sugarbaker DJ, Burt B, Peled A, Wald O. Ella E, et al. Among authors: yoon d. J Thorac Cardiovasc Surg. 2018 May;155(5):2164-2175.e1. doi: 10.1016/j.jtcvs.2017.11.110. Epub 2018 Feb 21. J Thorac Cardiovasc Surg. 2018. PMID: 29429629 Free article.
A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies.
Wilk J, Aggarwal V, Pauley M, Corey D, Conrado DJ, Lingineni K, Morales JF, Yoon DY, Zhang Y, Cui Z, Burton J, Larkindale J, Ma SC, Hovinga C, Martinez T, Romero K, Belfiore-Oshan R, Kim S; Duchenne Regulatory Science Consortium (D‐RSC) and the CINRG DNHS investigators. Wilk J, et al. Among authors: yoon dy. CPT Pharmacometrics Syst Pharmacol. 2024 Nov 27. doi: 10.1002/psp4.13281. Online ahead of print. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 39600251 Free article.
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. Abramson JS, et al. Among authors: yoon dh. Lancet. 2024 Nov 16;404(10466):1940-1954. doi: 10.1016/S0140-6736(24)01774-4. Lancet. 2024. PMID: 39550172 Clinical Trial.
2,734 results